1		
2	Cohor	rt Profile: ReCoDID Consortium's Harmonized Acute Febrile Illness Arbovirus
3	Meta-	Cohort
4	ReCo	DID Pooled Cohort Profile
5	Gustav	vo Gómez <sup>1°</sup> , Heather Hufstedler <sup>2°</sup> , Carlos Montenegro <sup>3°</sup> , Yannik Roell <sup>4</sup> , Anyela Lozano <sup>1</sup> ,
6	Adriar	na Tami <sup>5,6</sup> , Tereza Magalhaes <sup>7, 8</sup> , Ernesto T.A. Marques <sup>9,10</sup> , Angel Balmaseda <sup>3,11</sup> ,
7	Guilhe	erme Calvet <sup>12</sup> , Eva Harris <sup>13</sup> , Patricia Brasil <sup>12</sup> , Victor Herrera <sup>1</sup> , Luis Villar <sup>1,14</sup> , Lauren
8	Maxw	ell <sup>2</sup> , Thomas Jaenisch <sup>2, 4, 15</sup> , ReCoDID Arbovirus harmonization study group*
9 10 11	1.	Grupo de Epidemiología Clínica, Universidad Industrial de Santander, Bucaramanga,
12		Colombia
13	2.	Heidelberg Institute of Global Health (HIGH), Heidelberg University Hospital,
14		Heidelberg, Germany
15	3.	Sustainable Sciences Institute, Managua, Nicaragua
16	4.	Center for Global Health, Colorado School of Public Health, Aurora, Colorado, United
17		States of America
18	5.	University of Groningen, University Medical Center Groningen, Department of Medical
19		Microbiology and Infection Prevention, Groningen, The Netherlands
20	6.	Departamento de Estudios Clínicos, Facultad de Ciencias de la Salud, Universidad de
21		Carabobo, Valencia, Venezuela
22	7.	Center for Vector-Borne Infectious Diseases (CVID), Department of Microbiology,
23		Immunology and Pathology (MIP), College of Veterinary Medicine and Biomedical
24		Sciences, Fort Collins, CO, USA

25	8.	Department of Preventive and Social Medicine, School of Medicine, Universidade
26		Federal da Bahia, Salvador, BA, Brazil

- 27 9. Institute Aggeu Magalhães, Department of Virology and Experimental Therapeutics,
- 28 Fundação Oswaldo Cruz, FIOCRUZ-PE, Recife Brazil
- 29 10. University of Pittsburgh, School of Public Health, Department of Infectious Diseases and
- 30 Microbiology, Pittsburgh, PA, USA
- 31 11. Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia,
- 32 *Ministry of Health, Managua, Nicaragua.*
- 33 12. Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brasil
- 34 13. Division of Infectious Diseases, School of Public Health, University of California
- 35 Berkeley, Berkeley, CA, USA
- 36 14. Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga,
- 37 Colombia
- 38 15. Section Clinical Tropical Medicine, Department for Infectious Diseases, Heidelberg
- 39 University Hospital, Heidelberg, Germany
- 40 ° *Co-first authors, in alphabetical order*
- 41 \* Membership of the ReCoDID Arbovirus harmonization study group is provided in the
- 42 acknowledgements

## 43 Abstract

Infectious disease (ID) cohorts are key to advancing public health surveillance, public policies and 44 pandemic responses. Unfortunately, ID cohorts often lack funding to store and share clinical-45 epidemiological data (CE) and high-dimensional laboratory (HDL) data long-term, which is 46 evident when the link between these data elements is not kept up to date. This becomes particularly 47 apparent when smaller cohorts fail to successfully address the initial scientific objectives due to 48 limited case numbers, which also limits the potential of pooling for these studies to monitor long-49 50 term cross-disease interactions within and across populations. To facilitate advancements in crosspopulation inference and reuse of cohort data, the European Commission (EC) and the Canadian 51 Institutes of Health Research, Institute of Genetics (CIHR-IG) funded the ReCoDID 52 53 (Reconciliation of Cohort Data for Infectious Diseases) Consortium to store and share harmonized and standardized CE and HDL data on a federated platform and also provide innovative statistical 54 tools to conduct meta-analyses of the individual patient data. Here we describe the harmonization 55 of CE data from nine arbovirus (arthropod-borne viruses) cohorts in Latin America, which serve 56 as a starting point for the ReCoDID meta-cohort. CE data was retrospectively harmonized using 57 Maelstrom's methodology and standardized to Clinical Data Interchange Standards Consortium 58 (CDISC). 59

This meta-cohort will facilitate various joint research projects, e.g., on immunological interactions
between sequential flavivirus infections and for the evaluation of potential biomarkers for severe
arboviral disease.

- 63
- 64
- 65
- 66

## 67 Introduction

The meta-cohort consists of participant-level data and descriptive metadata from nine studies from five countries (Brazil, Colombia, El Salvador, Nicaragua, and Venezuela). All studies were established to study arbovirus (arthropod-borne viruses) infections in the population, with some cohorts enrolling maternal-infant pairs, or either children or pregnant women.

Most studies did not recruit participants through study-initiated contacts (e.g., emails, calls, letters, etc.). Instead, the vast majority of participants in each cohort were directly referred to the study from the health unit where they were seeking care. A small fraction of participants contacted the cohorts directly to participate because participation was associated with access to more routine care or additional screenings, which can be seen as a benefit in resource-poor settings.

The interactions between immune responses caused by different patterns of exposure over time to the four dengue virus serotypes (DENV 1-4) and Zika virus (ZIKV) have attracted considerable attention - for example as a mechanism to explain the heterogeneity in severe dengue but also in the severe outcomes seen during and after the ZIKV epidemic in Latin America(1–5). The investigation of these interactions between closely related members of the *flaviviridae* requires large sample sizes and the inclusion of populations with exposures to different sequences of pathogens, resulting in heterogeneous immune profiles.

84

The ReCoDID Consortium, funded by the EC and CIHR-IG(6), aims to provide ID researchers with harmonized participant-level data and metadata resources as well as analysis tools to facilitate pooled analysis projects, i.e. to advance our knowledge on the effects of prior exposure on the immune response to subsequent epidemics at the population and individual level and to inform personalized medicine approaches to diagnosis and treatment of infections. To facilitate cross-

study inference in the context of emerging IDs, ReCoDID researchers created a platform to extract 90 individual-level CE and HDL data from existing cohorts, and harmonize this data according to a 91 specific standard. ReCoDID focuses current harmonization efforts on arbovirus and SARS-CoV-92 2 cohort data, but hopes to expand these services to other IDs in the future. This cohort profile 93 provides an overview of the newly-created arbovirus meta-cohort from five countries: Brazil, 94 95 Colombia, El Salvador, Nicaragua, and Venezuela. Acute and post-acute samples were collected from each study. Information extracted from samples vary from study to study and include DENV 96 molecular tests, DENV serotype, DENV viral load, ZIKV molecular test,, ZIKV viral load, 97 98 CHIKV molecular tests and CHIKV viral load. Height, weight, birthdate, negative health outcomes associated with severe dengue (such as occurrence of bleeding, e.g.) and required 99 interventions have also been collected. The ReCoDID Consortium aims to build a data sharing 100 101 platform for linking CE data to HDL data (e.g., human and pathogen genomic data, human metabolomic and immunomics data) at the participant level that are collected from ID focused 102 cohorts. While ReCoDID is working to share data related to other disease types, this paper 103 describes the acute febrile illness (AFI) meta-cohort that includes, at the date of publishing this 104 article, data from nine studies that have committed to sharing CE and HDL data from their 105 106 arbovirus cohorts. All participating cohorts have submitted genomic sequences of the DENV virus to ReCoDID, except for the cohorts in Nicaragua and the Cohort of Symptomatic Pregnant Women 107 in Brazil. Two studies- PHBDC and IDAMS cohorts- have also agreed to share genomic 108 109 sequences for CHIKV and ZIKV viruses. Most participating cohorts collected and stored blood samples; Nicaragua also collected urine and saliva samples. Cohorts varied in their inclusion 110 criteria- some admitting only patients who present with fever, some used rash or red eyes, while 111 112 others admitted patients who presented with fever and/or rash. With the introduction of ZIKV and

113 CHIKV, the PHBDC study chose to adjust the inclusion criteria in order to admit patients who 114 presented with rash, headache and/or fever. Altogether, the longitudinal data of the meta-cohort 115 covers over 18,000 patients (pediatric and adults), in both inpatient and outpatient settings from 116 five countries (Brazil, Colombia, El Salvador, Nicaragua, and Venezuela). Data collection start 117 and end dates vary between cohorts, but ranged from 1998 to the present where the patients have 118 been followed up during different intervals as it can be identified in the table 1 below:

119

### 120 Table 1. Frequency of follow-up across included cohort studies

Study		Arm	Frequency of clinical observations	Frequency of laboratory investigations (not for diagnosis)	Frequency of laboratory Diagnosis (example 0,7,14)
Col: AEDES	Outpatient/Inpatient	3-5, 4-6, 5-7, 15-17	3-5, 4-6, 5-7, 15-17	3-5, 4-6, 5-7, 15- 17	
		Outpatient/Inpatient	Once per day (Inpatient)	0-7 days, 3-6, and 24 weeks Note: Inpatients also provided samples every 48 hours during hospitalization (up to 4 samples)	0
Col: Piedecuesta's household-based dynamic cohort. Identification of age groups to be prioritized for vaccination in a population of children and adolescents		Outpatient	Biweekly (All, telephone) Once per day (Incident Febrile cases)	Once per day (Incident Febrile Cases)	Annual (All) 0, 7 days (Incident Febrile cases)
		Outpatient	Once per day	Once per day	0,14
Col:AEDES Cohorts	evaluation of its usefulness to identify early conditions	Outpatient	Once per day	Once per day	0,14
		Outpatient	Once per day	0, 6	0,10
	1	Inpatient	Once per day	Once per day	0,10
		Placebo	Enrollment, 6 y 12 (Months) (Incident Febrile Cases)	Daily (Incident Febrile Cases)	0-5, 14 (Incident Febrile Cases)
		Outpatient	Once per day	Once per day	0,1,2;14-28
Nica-Pediatric Dengue Hospital-based Study -		Inpatient	More than once per day	Once per day	0,1,2,14-28
		Follow-up	2-3 times per week	2-3 times per week	0,14-21
Nica-PDCS		Annual sample		Once per year.	0

IDAMS	Recruitment as outpatients, some proceeded to hospitalization	Once per day	Once per day	0,3-6,15 (days)
Cohort of symptomatic pregnant women		At enrollment, weekly telephone follow-up, and a second visit within 30 days after enrollment	NA	0, 30

121

122

123 Evaluation of the diagnostic accuracy and usefulness of rapid tests for early diagnosis of dengue124 (Diagnosis Cohort)

The diagnosis cohort, funded by E25bio, Inc., was aimed to determine the diagnostic usefulness of repeated NS1 rapid testing in clinical settings(7). This cohort enrolled and followed patients ( $\geq$ 2 years old) who had both clinically suspected dengue and a positive dengue rapid test (NS1 antigen) at the time of consultation or hospitalization. Participants were followed at 1, 2, and 10 days (convalescence) after recruitment to determine the incidence of dengue complications among confirmed cases. Dengue infection was defined as positive NS1 results (acute sample).

131

132

133 Immune Mechanisms of Pathogenesis in Patients with Dengue Infection (Prognosis Cohort)

The Prognosis Cohort began with the goal to prospectively validate the predictive accuracy of a pool of transcriptomics intended to predict severity among patients with confirmed DENV infection(8). This study was funded by the U.S. Department of Defense and Colombia's Centro de Atención y Diagnóstico de Enfermedades Infecciosas (CDI, Colombia). This cohort enrolled patients ( $\geq$  1 year old) with clinically suspected dengue and conducted follow-up at 1, 2, and 10 days (convalescence) after recruitment to determine the incidence of dengue complications among confirmed cases. Participants recruited in outpatient settings were clinically evaluated at enrolment

and asked to provide additional blood samples between 3-6 days and 7-10 days if their first sample was obtained up to 2 days and 3-4 days after the onset of fever, respectively. Those who were recruited from inpatient settings underwent daily clinical evaluation, and blood samples were drawn every 48 hours during hospitalization (up to 4 samples). In all participants, additional samples were collected 3-6 and 24 weeks after onset of fever(9,10). Dengue infection was defined as positive PCR results (acute sample).

147

### 148 Piedecuesta's Household-Based Dynamic Cohort (PHBDC)

149 Piedecuesta's household-based dynamic cohort sought to estimate age-specific dengue seroprevalence and identify age groups to be prioritized for vaccination among children and 150 adolescents. This study was funded by the Colombian Science Ministry, Minciencias. PHBDC was 151 152 a population-based cross-sectional study which began in 2014 and enrolled and evaluated healthy children and adults (15%) from Piedecuesta (a mid-size city with endemic DENV). The aim of the 153 study was to estimate age-specific dengue seroprevalence in order to identify age groups to be 154 prioritized for vaccination among children and adolescents. Based on the results of this 155 seroprevalence study, a household-based dynamic cohort was initiated in 2015 with the aim of 156 estimating the age-specific incidence of dengue in Piedecuesta (N=2,730). This cohort enrolled 157 children (2-15 years old) and adults within the same household. The cohort followed up with 158 participants on a biweekly basis through telephone contact to identify incident febrile cases. Cases 159 160 were identified through clinical evaluation, and blood samples studied using Luminex ArboMIA to determine etiological diagnosis (annual [2016-2017] cumulative incidence: 6.0%). Additionally, 161 this cohort conducted annual visits to the participants' residences to collect blood samples to 162 163 determine dengue seroconversion (losses to follow-up: 6.5% and 3.2% during the first and second

year, respectively), a strategy that allowed for the estimate of attack rates to be calculated for
chikungunya (22%) and ZIKV (34%) during the outbreaks of 2015 and 2016, respectively(11).

166

167

### 168 Abordando Áreas Endémicas del Dengue para el Estudio de su Severidad (AEDES) Cohorts

The AEDES cohorts' data is an amalgamation of three independent studies, which were assembled 169 with the aim of developing and validating diagnostic and prognostic algorithms for DENV funded 170 by the same national agency above, Minciencias. The first two cohorts were initiated and 171 172 conducted during endemic periods (2003-2004, n=500; and 2006-2008, N=705) and a third one during an epidemic (2009-2011, N=2,004). These studies shared similar enrolment protocols: 173 febrile patients with clinically suspected dengue were recruited at the point of care. Whereas the 174 175 first two cohorts were conducted in outpatient settings of Bucaramanga, the third (the AEDES cohort- see Table 2 for clarification) was a multicenter study that enrolled and followed 176 individuals in both outpatient (Bucaramanga, Barranquilla, and Palmira) and inpatient 177 (Bucaramanga, Cali, Neiva, and Palmira) settings. Patients in the first two cohorts came in for 178 follow-up visits one to seven days via clinical and laboratory assessments (median follow-up: 4 179 and 3 days, respectively), with a convalescent blood sample taken approximately 2 weeks after 180 disease onset. The third study which enrolled participants from outpatient and inpatient settings 181 had median follow-up times of 3 and 2 days, respectively. Dengue infection was defined as an 182 183 ELISA IgM/IgG seroconversion or four-fold increase in titers in paired samples or virus isolation (acute sample) in the first two cohorts, and as an ELISA IgM/IgG seroconversion or four-fold 184 increase in paired samples, or positive ELISA NS1 or PCR, or viral isolation (acute sample) in 185 186 AEDES(12).

188

189 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents
190 Aged 9 to 16 years in Latin America - placebo arm (CYD15)

Participants in the CYD15 were healthy children and adolescents (9-16 years old) who were 191 192 recruited from a placebo arm of a randomized control trial funded by Sanofi Pasteur and had the primary goal of evaluating the efficacy of the chimeric yellow fever-dengue-tetravalent (CYF-193 DTV) dengue vaccine. The CYD15 study was a multicenter, placebo-controlled, randomized, 194 195 observer-blind phase III DENV vaccine efficacy clinical trial, examining the efficacy of a vaccine 196 to prevent symptomatic virologically-confirmed dengue cases in infants. Participants were randomly assigned, in a 2:1 ratio, to receive three doses of the Recombinant, live, attenuated, 197 198 tetravalent dengue vaccine. CYD-TDV. (treatment group) or placebo (0.9% sodium chloride: control group) within 1 year. Participants included in this meta-cohort were healthy children and 199 adolescents between 9-16 years old from the placebo arm living in Bucaramanga, Colombia. 200 Volunteers were invited to participate through contacts with schools in the metropolitan area, 201 referred by relatives of participants, or recruited by community leaders. Participants were followed 202 through biweekly phone calls. In case of identifying any febrile episode, participants were asked 203 to provide blood samples to perform virological confirmation and ELISA (NS1, IgM/IgG) testing 204 for dengue infection as well as hemogram and hepatic function tests. Additional ELISA (IgM/IgG), 205 206 hemogram and hepatic function tests were repeated in a convalescent sample collected up to 21 days after fever's onset(13). 207

208

209 *Pediatric Dengue Cohort Study (PDCS)* 

The PDCS was established as a community-based cohort in District II of Managua, Nicaragua in
2004. The cohort was initially established to study DENV transmission and to characterize

symptoms and disease spectrum. It has since evolved to study the virologic and immunologic 212 determinants of response to sequential DENV and ZIKV infections, epidemiological risk factors 213 for infection and disease, and expanded to include other arboviruses, including CHIKV(14.15). 214 The cohort has been funded by a variety of sources, including the US National Institutes of Health 215 (NIH) National Institute of Allergy and Infectious Disease (NIAID), the Pediatric Dengue Vaccine 216 217 Initiative of the International Vaccine Institute (IVI), the Bill and Melinda Gates Foundation, among others. PDCS is a community-based cohort study which enrolled 2-9-year-olds in August 218 2004. Participants were originally invited to remain in the study until their 12th birthday, but the 219 220 restriction increased to 15 in 2007, and 18 in 2019(16). Each year, new two-year old children are enrolled, and additional replacement enrollment is performed as needed in the older age groups to 221 maintain the cohort's age structure. At any given time, there are roughly 3,800 - 4,100 children 222 223 actively participating in the PDCS(17,18). With the introduction of chikungunya virus (CHIKV) and ZIKV into Latin America and specifically Nicaragua, CHIKV and ZIKV were added to the 224 225 PDCS in 2014 and 2015, respectively. Visits are divided into 4 categories (A-D) based on symptomatology(19). Category A cases include fever plus symptoms and signs of suspected 226 dengue (WHO's case definition). Category B cases are undifferentiated febrile illnesses. Category 227 228 C cases are fevers with a non-arboviral diagnosis (e.g., influenza, UTI), and category D cases are non-febrile cases. With the introduction of ZIKV, the D case category was divided into two 229 230 subsets, D cases with ZIKV-like symptoms such as red eyes and rash and D cases without ZIKV-231 like symptoms(20).

232

Category A, B, and ZIKV-like D cases are tested for DENV, ZIKV, and CHIKV using RT-PCR
and serological testing. Acute (1-4 days post-onset of symptoms) and convalescent (14-21 days)

samples are collected from all suspected cases. An additional sample is collected at day 4-6 from
RT-PCR-confirmed DENV and ZIKV cases for immunological studies(21). Each year, a healthy
blood sample (serum/plasma, and PBMCs prepared from a subset) is collected and used (a) to
detect arbovirus infections that may not have been apparent but may have occurred throughout
the year and (b) for additional immunological studies. Data on socioeconomic factors,
demographics, and medical history are collected at enrollment and are updated annually. During
clinical visits, detailed information on symptoms and symptom onset is collected(22).

242

### 243 Pediatric Dengue Hospital-Based Study (PDHS)

This cohort was founded in 1998 to investigate the clinical, immunological, and viral risk factors 244 for severe DENV, assessing biomarkers, and studying immune responses over time. This study 245 246 has been supported by the NIAID at NIH through various mechanisms. The Pediatric Hospital-Based Study began in 1998 and enrolls children ages 6 months to 14 years who present to the 247 Hospital Infantil Manuel de Jesus Rivera (HIMJR) with suspected dengue (< 7 days from illness 248 onset)(23). Both in-patient and out-patient suspected cases are eligible for enrollment. Upon 249 enrollment, a complete physical exam is performed, and medical history is collected. Participants 250 251 are followed throughout the acute phase of their illness and data including vital signs, symptoms, and treatment are recorded daily. Blood samples for complete blood counts, molecular, serological, 252 and virological testing are collected daily for the first three days. An additional convalescent 253 254 sample is collected 14-21 days after enrollment. A longitudinal arm of this study, for those participants who consent, collects samples 3-, 6-, 12-, and 18-months post-illness for 255 immunological studies. The protocol was amended in 2014 to include CHIKV and again in 2016 256 257 to include ZIKV.

258

259 International Research Consortium on Dengue Risk Assessment, Management and Surveillance
260 (IDAMS)

The primary objective of the IDAMS Cohort was to evaluate warning signs and predictors or 261 biomarkers associated with progression to severe dengue in order to facilitate triage efforts. 262 Funding was provided by the EC's Seventh Framework Program. The IDAMS study (2011-2016) 263 was a prospective multi-center acute febrile illness study conducted in Vietnam, Cambodia, 264 Malaysia, Indonesia, Brazil, Venezuela, and El Salvador. Sites recruited participants who with a 265 266 history of fever for ≤72-84 hours (site-dependent), presenting with clinical symptoms suggestive of dengue (in patients >5 years of age). Patients were excluded if a) they presented with severe 267 dengue at enrolment, b) a clinician judged the patient was unlikely to attend daily outpatient 268 follow-up visits, or c) the clinical presentation strongly suggested a diagnosis other than dengue 269 (e.g., pneumonia, otitis, etc.). Only the data from Latin America were considered for the meta-270 271 cohort. However, as the data structure is homogenous, other study locations could be added in the 272 future. The study design was described before in detail (24,25). In brief, patients with a history of fever for less than 72-84 hours (site dependent) and suggestive of DENV were recruited in 273 274 outpatient clinics across the participating sites and followed up daily for a maximum of 6 days or until afebrile for 48h, with a final follow-up visit around day 10-14 of illness. Daily follow-up 275 276 included physical examination as well as simple laboratory investigations such as full blood count. 277 Dengue infection was defined as confirmed positive by either PCR or ELISA NS1 result in acute 278 sample.

279

### 281 Cohort of Symptomatic Pregnant Women

In 2012, a prospective cohort for dengue surveillance in mother-infant pairs was established within 282 the Manguinhos, Rio de Janeiro area. In 2015, however, most of these were later identified as 283 ZIKV cases. To identify these ZIKV cases in the Rio de Janeiro population, the pregnancy cohort 284 study was modified to enroll women who presented with a rash at any week of gestation. It was 285 286 supported by the Department of Science and Technology (Departamento de Ciência e Tecnologia-DECIT) of the Brazilian Ministry of Health (Ministério da Saúde) and funded by the Coordination 287 of the Improvement of Higher Level Personnel (Coordenação de Aperfeiçoamento de Pessoal de 288 289 Nível Superior-CAPES); the Bill and Melinda Gates Foundation, Grand Challenges Explorations; and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of 290 Health. Brazil's Symptomatic Women cohort offered enrollment between September 2015 to 291 292 September 2016 to pregnant women who attended the acute febrile illness clinic at the Oswaldo Cruz Foundation and who presented with a rash that had developed in the previous 5 days, with or 293 without an associated fever. Laboratory data was collected after enrollment(26). Weekly follow-294 ups occurred over the phone, and clinical and laboratory follow-up occurred within 30 days of 295 enrollment and were referred for fetal ultrasonography follow-ups at three timepoints: before 20 296 weeks of gestation, between 20-30 weeks of gestation, and after 30 weeks of gestation. ZIKV 297 infection was defined as positive RT-PCR, in acute samples of blood or urine. 298

#### Table 2: Summary of studies in the Meta-Cohort

Country	Study			Years Study Included was pediatric Conducted cohorts		Study Status	Ν	Adherence*							
				Conducted	cohorts			Mean age (yr)	Annual Loss to follow-up		Followed	1		Lost	
									(%)	Mean age (yr)	Female (%)	Confirmed Dengue (%)	Mean age (yr)	Female (%)	Confirmed Dengue (%
COL		agnosis Cohort (Evaluation of the diagnostic efulness of rapid tests for early diagnosis of		2019-2021	x	Completed	28	20.5	10.7	21.1	60	40	8.0	33.3	33.3
	Prognostic Cohort (Immune Mechanisms of Pathogenesis in Patients with Dengue Infection) PHBDC (Piedecuesta's household-based dynamic cohort: Identification of age groups to be prioritized for vaccination in a population of children and adolescents)			2019-2021	x	Completed	256	13.4	5.5	13.4	47.1	100	13.1	35.7	100
       				2015-2018	x	Completed	2730	12.6	10.1	14.6	51.2	6.0	12.3	48.5	NA
	A E D	Identification of prognostic markers of sev	verity in dengue	2003-2004	x	Completed	500	24.7	NA	24.7	51.2	39.0	NA	NA	NA
	E S c o	E Validation of a clinical definition for deng c of its usefulness to identify early condition o hospitalization		2006-2008	x	Completed	705	26.5	NA	26.5	42.8	32.3	NA	NA	NA
	h o r	AEDES (Abordando Áreas Endémicas del Dengue para el Estudio de su	Outpatient	2009-2011	x	Completed	1008	21.7	NA	21.7	48.2	38.6	NA	NA	NA
NICA PE IDAMS ID	Severidad). Colombian multicentric study.	Inpatient			Completed	996	14.8	NA	14.8	47.3	41.2	NA	NA	NA	
	de	CYD15 (Placebo Arm): Efficacy and safety of a new tetravalent dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America		2011-2017	x	Completed	484	12.0	13.0	12.0	51.8	8.3	12.0	48.0	3.2
NICA	PI	DCS (Pediatric Dengue Cohort Study)		2004- ongoing	x	Ongoing	9,699	6	4.3#	7.9	49.00	11.5	NA	NA	NA
	PDHS (Prospective Hospital-Based Study of Dengue Classification, Case Management, and Diagnosis)		1998- ongoing	x	Ongoing	2,659	13	7.03	8.59	48.10	53.7	NA	NA	NA	
atin		AMS (International Research Consortium or sessment, Management and Surveillance)**		2012-2016		Completed	1625	19.3	2.7*	19.0	47.6	28.8	13.4	86.4	NA
BRA	Co	bhort of Symptomatic Pregnant Women		2015- 2016		Completed	383	6.27	13.6	29.77	86.40	0	27.56	13.60	0

### 304Table 3. Summary of ethics approvals and consent among patients

	Study	Did you obtain ethics approval for this study?	Start date	End date	Type of informed consent obtained	Does the study include minors?	Was Informed parental consent obtained for minors?	Was informed consent obtained for adults?
diagnostic ac	is Cohort: Evaluation of the ccuracy and usefulness of rapid tests gnosis of dengue	Yes	January 23, 2020	June 01, 2020	Written	Yes	Yes	Yes
	is: Immune Mechanisms of s in Patients with Dengue Infection	Yes	March 18, 2019	February 20, 2020	Written	Yes	Yes	Yes
Col: Piedecuesta's household-based dynamic cohort. Identification of age groups to be prioritized for vaccination in a population of children and adolescents.		Yes	June 1, 2015	December 30, 2018	Written	Yes	Yes	Yes
	Identification of prognostic markers of severity in dengue	Yes. A copy of IRB approval obtained in 2003 was requested.	April 01, 2003	March 30, 2005	Written	Yes	Yes	No
Col:AEDES Cohorts	Validation of a clinical definition for dengue and evaluation of its usefulness to identify early conditions associated with hospitalization	Yes. A copy of IRB approval obtained in 2005 was requested.	February 01, 2006	April 30, 2008	Written	Yes	Yes	NA
	"AEDES: Abordando Áreas Endémicas del Dengue para el Estudio de su Severidad". Colombian multicentric study.	Yes	May 01, 2009	May 30, 2011	Written	Yes	Yes	NA
dengue vacci	acy and safety of a new tetravalent ine in healthy children and aged 9 to 16 years in Latin America	yes	Jun 15, 2011	Feb 28, 2018	Written	Yes	Yes	Yes

Pediatric Dengue Cohort Study (PDCS) (Nicaragua)	Yes	August 31, 2004	ongoing	Informed consent, parental; verbal assent	Yes	Yes	Yes
Pediatric Dengue Hospital-Based Study (PDHS) (Nicaragua)	Yes	August 4, 2005	ongoing	Informed consent; verbal assent; written assent	Yes	Yes	Yes
IDAMS (Carabobo, Venezuela)	Yes	September 27, 2013	November 14, 2016	Written	Yes	Yes	Yes
IDAMS (Rio de Janeiro, Brazil)	Yes	April 6th, 2015	May 9th, 2016	Written	Yes	Yes	Yes
Cohort of Pregnant Women (Brazil)	Yes	September 1 <sup>st</sup> , 2015	May 30 <sup>th</sup> , 2016	Written	Yes	Yes	Yes

306

# Retrospective and Prospective Harmonization Efforts of the Meta-Cohort

Individual patient data (IPD) meta-analyses (MA) are considered the gold standard for meta-analyses(27)The strength of conducting IPD-MAs, as opposed to standard meta-analyses using effect estimates, is the opportunity to control for baseline heterogeneity

Knowing that we had a collective wealth of arbovirus data, we initially set out to find a 312 313 common data dictionary for all cohorts within the ReCoDID consortium. This effort included 314 trying to find common variables across all zika cohorts, then across dengue cohorts, as well as any 315 chikungunya patients. As mentioned in the literature, there has not been a gold standard method 316 for data harmonization, but we eventually found the Maelstrom Guide to Rigorous Retrospective Harmonization (28). The first step of the guide is to define a research objective for harmonization, 317 318 which allowed us to focus on the dengue studies based on a research question that aimed to identify 319 future flavivirus clinical epidemiology in settings where we can infer the past history of infections. 320 Once we had a focused research question, the next step was implementing a well-defined structure of dimensions (endpoints/confounders/exposure) and domains to tackle from a medical 321 perspective. These dimensions guided us in establishing a set of medical meetings where we 322 identified, prioritized and defined in a semantic manner the variables to include in the master data 323 dictionary as indicated in the methodology used and explained in the Fig 1. 324

325 Fig 1. Harmonization process.

326

Then we compared each study data dictionary against the reconciled master data dictionary establishing a harmonization potential based on a predefined structure of conventions

that gave us a complete set of variables with different levels of potential use for harmonization,
this can be identified in the Fig 2.

- 331 Fig 2. Harmonization potential
- 332

Retrospective harmonization is generally resource-intensive (29,30), as we can attest to. In order to facilitate future IPD-MAs, we are in the process of creating a Case Report Form which we then standardized according to the CDISC data standard. The hope is that future cohorts conducting arbovirus research will be able to prospectively implement this CRF, decreasing, or removing entirely, the effort and cost of retrospectively harmonizing data to be pooled in an IPD-MA.

339

# <sup>340</sup> What has it found? Key findings and publications

Key findings include: 1) low serum 25(OH)D concentrations in patients predicted the progression of dengue fever(31); 2) the highest risk group for severe dengue being patients with preexisting anti-DENV antibody titers; the same study showing a preventative effect in those patients who have a (very) high level of antibody titers(32); and 3) the development, validation, and evaluation of the usefulness of a scale for the prediction of disease severity among confirmed cases of dengue (32%, 39%, and 41% for the three cohorts).

347

348

349

# What are the main strengths and weaknesses of the combined meta-cohort effort?

A technical strength of the Consortium's efforts is the retrospective harmonization of participant-353 level data which has been completed according to the Maelstrom group's recommendations for 354 best practice(28), which outlines steps 0 (define the research question) to 5 (disseminate and 355 preserve final harmonization products). Maelstrom Research guidelines' Step 0 is why the 356 ReCoDID Consortium's data outlined in this profile is primarily focused on dengue-related 357 outcomes despite collecting data related to viruses. Another strength is the use of CDISC/SDTM 358 standards as reference for the definition of the core variables harmonized (33), which enables 359 interoperability between the meta-cohort and other studies that apply CDISC SDTM. The 360 harmonization (processing data collected by studies und a common variable format), or 361 362 standardization (use of a data standard (CDISC, e.g.) to define the core variables format to be generated, required to conduct individual-level meta-analyses can be extremely resource-363 demanding. Going forward, and in order to minimize this burden and improve individual-level 364 patient data meta-analyses (IPD-Mas), the ReCoDID Consortium recommends the creation of a 365 standard case report form (CRF) for acute viral syndrome (arbovirus) research, which includes the 366 features of the overlapping clinical syndromes associated with the most important arboviruses 367 (e.g., DENV, ZIKV, CHIKV, etc.), to be used by all partner studies in the future. Potentially, this 368 CRF will include modules for different severe disease manifestations that can be adapted to the 369 370 local situation (i.e., bleeding module, neurological module, liver pathology module).

371

Another strength of the combined cohort is that it covers different countries and partner sites across
Latin America - each of which experienced slightly different histories of DENV serotypes,

374	CHIKV, and ZIKV infections over the last decades. The resulting 'experiment of nature'
375	represents a population immune landscape that we now would like to prospectively follow with
376	future cohorts, considering the potential of immunological interaction between related flaviviruses
377	(e.g., DENV1-4 and ZIKV). In Fig 3 and Fig 4, created using R (4.0.5)(34), we present DENV,
378	ZIKV, and CHIKV activity over time in the respective countries and partner sites. This combined
379	cohort is a first step towards the direction of a multicentric arbovirus cohort, which needs to be
380	complemented with advanced technology assessing immunological history, additional investments
381	in future harmonization, and standardization.

382

<b>Fig 3.</b> DENV serotype distribution over time.	<b>Fig 4.</b> Reported number of cases for DENV, ZIKV and CHIKV over time
<ul> <li>a) Pernambuco (Brazil) *</li> <li>b) Ceará (Brazil) Δ</li> <li>c) Rio de Janeiro (Brazil) Δ</li> <li>d) Nicaragua §</li> <li>e) Colombia ∞</li> <li>f) Venezuela #</li> </ul>	<ul> <li>a) Pernambuco (Brazil) ∐, ∑,+</li> <li>b) Ceará (Brazil) ∐, +</li> <li>c) Rio de Janeiro (Brazil) ∐,</li> <li>d) Nicaragua §</li> <li>e) Colombia ∞</li> <li>f) Venezuela **</li> <li>g) El Salvador</li> </ul>

\* Data of annual DENV serotypes from PE, provided by: the Central Laboratory of Pernambuco (Laboratório Central de Pernambuco-LACEN PE) △ Data of annual DENV serotypes from CE and RJ, retrieved from the national online database of the Brazilian Ministry of Health

This data was derived from the Colombian National Institute of Health. http://portalsivigila.ins.gov.co/Paginas/Vigilancia–Rutinaria.aspx) # Dengue incidence data (1997-2014), Data from: the National Surveillance System of the Venezuelan mandatory notification diseases, the Ministry of Health (http://www.mpps.gob.ve). Data on the proportion of dengue cases per serotype in Aragua, provided by: the Laboratorio Regional de Diagnóstico e Investigación del Dengue y otras Enfermedades Virales (LARDIDEV), Corporación de Salud Aragua, Maracay, Venezuela, and published in Lizarazo Forero, EF (2019). Epidemiology, genetic diversity and clinical manifestations of arboviral diseases in Venezuela. PhD Thesis. University of Groningen, Groningen, the Netherlands. https://doi.org/10.33612/diss.108089934 II Data of annual DENV, ZIKV and CHIKV, reported cases in the states of Ceará (CE), Pernambuco (PE) and Rio de Janeiro (RJ), retrieved from: the national

[] Data of annual DENV, ZIXV and CHIKV, reported cases in the states of Ceara (CE), Pernambuco (PE) and Rio de Janeiro (RJ), retrieved from: the national online database of the Brazilian Ministry of Health (https://datasus.saude.gov.br/informacoes-de-saude-tabnet/, accessed on 11/8/21 to 11/11/21), except for CHIKV in 2015-2016 in CE and PE (see below). Data of CHIKV from CE and PE (2015-2016), taken from: Epidemiological Bulletins (EBs) published by the Brazilian Ministry of Health.

∑ Data for ZIKV from PE (2015), may be subject to reporting bias. At the time, ZIKV was largely unknown and therefore ZIKV cases might have been classified/notified as dengue cases, de Brito et al. (2016), Data from: Rev Soc Bras Med Trop 49(5):553-558, September-October, 2016 doi:10.1590/0037-8682-0245-2016.

+ Data of CHIKV from CE and PE (2015-2016), Taken from; Epidemiological Bulletins (EBs) published by the Brazilian Ministry of Health. § PDCS arboviral case data (Oct 2004 - Mar 2021). Image one contains yearly level data of PCR confirmed Dengue cases, and image two contains DENV,

SPDCS arboviral case data (Oct 2004 - Mar 2021). Image one contains yearly level data of PCR confirmed Dengue cases, and image two contains DEN CHIKV and ZIKV confirmed symptomatic infections on a monthly basis.

\*\* a) Vincenti-Gonzalez MF, A Tami, EF Lizarazo, ME Grillet (2018), Data from: ENSO-driven climate variability promotes periodic major outbreaks of dengue in Venezuela. Scientific Reports, Apr 10;8(1):5727. doi: 10.1038/s41598-018-24003-z b) Data derived from: Boletines Epidemiológicos de Venezuela, currently found at https://www.ovsalud.org/publicaciones/documentos-oficiales/. c) Data from: Venezuela National EPI-12 notifications, weeks 1-29, (2016). d) PAHO/WHO Epidemiological weekly bulletins at https://www.paho.org/en/documents

<sup>(</sup>https://datasus.saude.gov.br/informacoes-de-saude-tabnet/, accessed on 11/8/21 to 11/11/21

385

386

# Can I access the data? Where can I find out more?

Interested parties will be able to access data dictionaries that include information on variables 389 across the datasets via BioStudies(35). After consultation with each cohort, linked harmonized and 390 curated human cohort data (CE and HDL) is planned to be made accessible through the European 391 392 Genome-phenome Archive (EGA)(36) platform to Data Users after their requests are evaluated by 393 the ReCoDID Data Access Committee (DAC). Researchers will be able to openly access the descriptive cohort metadata related to the meta-cohort via the EMBL-EBI Cohort Browser(37). 394 395 Cohorts sharing CE and HDLdata within the ReCoDID Platform are responsible for obtaining 396 regulatory and ethical approvals at the local, or, in the case of Brazil, national, level for data 397 sharing. Where cohorts' original informed consent forms did not include broad consent for future use of data, ReCoDID worked with cohorts to apply for a waiver of consent. The waivers of 398 399 consent submitted to the Commission of Ethics in Research, CONEP, Brazil's national ethics regulatory authority. The waivers of consent have been in process for one year and we expect we 400 401 will need two years to complete the CONEP review.. Samples will not be shared; however, the associated viral sequencing data can be shared and accessed openly at the European Nucleotide 402 Archive (ENA)(38). Any further associated and shared data types can be shared and retrieved from 403 the relevant EMBL-EBI resources(39). 404

405

The assessment of political, ethical, administrative, regulatory, and legal (PEARL) issues related to data sharing guided the implementation and activities of ReCoDID to promote ethical data

governance and sharing that carefully considers the perspective and context of Low and Middle 408 Income Countries (LMICs). Empirical research, bibliography reviews, and stakeholders' 409 consultations guided ReCoDID members' activities and informed the development of the 410 ReCoDID Data Governance Framework (DGF). The ReCoDID DGF is a high-level normative, 411 organizational, and technical document that describes the goals and principles by which the 412 413 ReCoDID functions, among them the FAIR (findable, accessible, interoperable, and reusable) data principles. The ReCoDID DGF also implements international standards and best practices for data 414 sharing to promote the public interest and advancement of science. It further describes how the 415 416 ReCoDID Platform functions and complies with data protection and privacy legislation, mainly the European Union (EU) General Data Protection Regulation (GDPR), and how it relates to other 417 countries' legislations considering international data transfers. The ReCoDID DGF is centred on 418 419 protecting the rights and interests of Data Subjects (patients and research participants) and different stakeholders that participate in the biomedical innovation ecosystem, including researchers and 420 information technology (IT) professionals that engage in biomedical research and develop the 421 infrastructure and tools that enable health data platforms. 422

423 ReCoDID acknowledges the challenges to promoting a biomedical innovation system that is 424 transparent, equitable, and participatory, that incorporates LMICs' context-specific perspectives. 425 This is deeply rooted in identifying and overcoming the PEARL barriers related to data sharing mentioned above, as well as the enablers and different strategies to guarantee and implement 426 427 ethical data sharing and governance. Addressing these PEARL barriers requires creating discussion forums, building research networks, and promoting best practices among academic 428 communities that call for the de-colonization of global health practices and challenge power 429 structures that support and perpetuate them. Therefore, the ReCoDID DGF and ReCoDID 430

431	Intellectual Property and Open Science Policy incorporate these elements and include issues
432	related to benefit sharing, authorship, attribution, and recognition, as well as the mechanism to
433	implement them.

For more information, please contact <u>ena-path-collabs@ebi.ac.uk</u>, with reference to the ReCoDID
Project. To share associated human cohort data, please contact the University of Heidelberg
(thomas.jaenisch@uni-heidelberg.de).

437

438

# 439 Funding

ReCoDID is supported by the European Union's Horizon 2020 Research and Innovation
Programme under Grant Agreement No. 825746 and the Canadian Institutes of Health Research,
Institute of Genetics (CIHR-IG) under Grant Agreement N.01886-000. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.



445

446

# 447 Conflict of Interest

448 None declared.

449

450

452	
-----	--

453

454

455	Acknow	ledgement	S
-----	--------	-----------	---

456

458

- 457 This work was supported by the ReCoDID Arbovirus harmonization study group:
- 459 Janet Achieng (Heidelberg Institute of Global Health (HIGH), Heidelberg University
- 460 *Hospital, Heidelberg, Germany)*
- 461 *Sonia Arguello* (Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brasil)

462 Gabriela Maria Marón Alfaro (Hospital Nacional de Niños Benjamín Bloom, San Salvador,

- 463 *El Salvador)*
- 464 *Till Bärnighausen* (Heidelberg Institute of Global Health (HIGH), Heidelberg University
- 465 Hospital, Heidelberg, Germany)
- 466 *Bruno Souza Benevides* (University of the State of Ceara, Fortaleza, Brazil)
- 467 Sarah Bethencourt (Departamento de Estudios Clínicos, Facultad de Ciencias de la Salud,
- 468 Universidad de Carabobo, Valencia, Venezuela)
- 469 Andrea Caprara (Departamento de Estudios Clínicos, Facultad de Ciencias de la Salud,
- 470 Universidad de Carabobo, Valencia, Venezuela)
- 471 *Priscilla M.D.G. César* (McMaster University, Institute on Ethics & Policy for Innovation
  472 (IEPI))
- 473 *Guy Cochrane* (European Molecular Biology Laboratory, European Bioinformatics Institute,
- 474 Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK)
- 475 *Monika Consuegra* (Centro de Atención y Diagnóstico de Enfermedades Infecciosas,
  476 Bucaramanga, Colombia)

477 *Fabio Otero* (Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga,
478 Colombia)

- 479 *Kerstin Rosenberger* (Heidelberg Institute of Global Health (HIGH), Heidelberg University
- 480 Hospital, Heidelberg, Germany)
- 481 *Anna M. Gajewski* (Sustainable Sciences Institute, Managua, Nicaragua)
- 482 Nadim Rahman (European Molecular Biology Laboratory, European Bioinformatics
- 483 Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK)
- 484 Bladimir Cruz (Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador)
- 485 *Guillermo Barahona Escobar* (Hospital Nacional de Niños Benjamín Bloom, San Salvador,
- 486 *El Salvador)*
- 487 Maria I. Estupiñán (Centro de Atención y Diagnóstico de Enfermedades Infecciosas,
  488 Bucaramanga, Colombia)
- 489 *Isabel Fortier* (*Research Institute, McGill University Health Centre, Montreal, Canada*)

490 Rosa Margarita Gélvez Ramírez (Centro de Atención y Diagnóstico de Enfermedades

- 491 Infecciosas, Bucaramanga, Colombia)
- 492 *María Fernanda Vincenti Gonzalez* (University of Groningen, University Medical Center

493 Groningen, Department of Medical Microbiology and Infection Prevention, Groningen, The494 Netherlands)

- 495 *Peter W. Harrison* (European Molecular Biology Laboratory, European Bioinformatics
  496 Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK)
- 497 **Suran Jayathilaka** (European Molecular Biology Laboratory, European Bioinformatics
- 498 Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK)
- 499 *Guillermina Kuan* (Sustainable Sciences Institute, Managua, Nicaragua)

500	Manish Kumar	(European	Molecular	Biology	Laboratory.	European	<b>Bioinformatics</b>	s Institute.

- 501 Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK)
- 502 *Luz Marina Leegstra* (Heidelberg Institute of Global Health (HIGH), Heidelberg University
- 503 Hospital, Heidelberg, Germany)
- 504 Erley Ferlipe Lizarazo (University of Groningen, University Medical Center Groningen,
- 505 Department of Medical Microbiology and Infection Prevention, Groningen, The Netherlands)
- 506 Luigi Marongiu (Heidelberg Institute of Global Health (HIGH), Heidelberg University
- 507 Hospital, Heidelberg, Germany)
- 508 Ágnes Molnár (Heidelberg Institute of Global Health (HIGH), Heidelberg University
- 509 Hospital, Heidelberg, Germany)
- 510 *Cesar Narvaez* (Sustainable Sciences Institute, Managua, Nicaragua)
- 511 *Federico Narvaez* (Sustainable Sciences Institute, Managua, Nicaragua)
- 512 Sergio Ojeda (Sustainable Sciences Institute, Managua, Nicaragua)
- 513 *Gabriele Rinck* (European Molecular Biology Laboratory, European Bioinformatics Institute,
- 514 Wellcome Genome Campus, Hinxton, Cambridge CB10 ISD, UK)
- 515 Ernesto Pleités Sandoval (Hospital Nacional de Niños Benjamín Bloom, San Salvador, El
  516 Salvador)
- 517 Frank Tobian (Heidelberg Institute of Global Health (HIGH), Heidelberg University
  518 Hospital, Heidelberg, Germany)
- 519 *José Victor Zambrana* (Sustainable Sciences Institute, Managua, Nicaragua)
- 520 16. Luana Damasceno (Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brasil)
- 521
- 522
- 523

# 524 References

- Katzelnick LC, Zambrana JV, Elizondo D, Collado D, Garcia N, Arguello S, et al. Dengue and Zika
   virus infection in children elicit cross-reactive protective and enhancing antibodies that persist
   long term. Sci Transl Med [Internet]. 2021 Oct 10 [cited 2022 Nov 7];13(614):eabg9478. Available
   from: /pmc/articles/PMC8693842/
- Petzold S, Agbaria N, Deckert A, Dambach P, Winkler V, Drexler JF, et al. Congenital abnormalities
   associated with Zika virus infection–Dengue as potential co-factor? A systematic review. PLoS
   Negl Trop Dis [Internet]. 2021 [cited 2022 Nov 7];15(1):e0008984. Available from:
   https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008984
- Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against
   dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc
   Natl Acad Sci U S A [Internet]. 2016 Jan 19 [cited 2022 Nov 8];113(3):728–33. Available from:
   https://pubmed.ncbi.nlm.nih.gov/26729879/
- Katzelnick LC, Coloma J, Harris E. Dengue: Knowledge gaps, unmet needs and research priorities.
   Lancet Infect Dis [Internet]. 2017 Mar 1 [cited 2022 Nov 7];17(3):e88. Available from:
   /pmc/articles/PMC5967882/
- 5. Katzelnick LC, Harris E, Baric R, Coller BA, Coloma J, Crowe JE, et al. Immune correlates of
  protection for dengue: State of the art and research agenda. Vaccine [Internet]. 2017 Aug 8
  [cited 2022 Nov 7];35(36):4659. Available from: /pmc/articles/PMC5924688/
- 6. ReCoDID | Reconciliation of Cohort data in Infectious Diseases [Internet]. [cited 2022 Nov 7].
  Available from: https://recodid.eu/
- 545 7. Díaz FA, Martínez RA, Villar LA. Criterios clínicos para diagnosticar el dengue en los primeros días
  546 de enfermedad. Biomédica [Internet]. 2006 Mar 1 [cited 2022 Nov 7];26(1):22–30. Available
  547 from: https://revistabiomedica.org/index.php/biomedica/article/view/1391
- 5488.Villar LA, Gélvez RM, Rodríguez JA, Salgado D, Parra B, Osorio L, et al. Biomarcadores pronósticos549de gravedad del dengue. Biomédica [Internet]. 2013 Aug 1 [cited 2022 Nov 7];33(SUPPL.1):108–55016. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/733/2275
- 5519.Villamor E, Villar LA, Lozano A, Herrera VM, Herrán OF. Vitamin D serostatus and dengue fever552progression to dengue hemorrhagic fever/dengue shock syndrome. Epidemiol Infect [Internet].5532017 Oct 1 [cited 2022 Nov 7];145(14):2961. Available from: /pmc/articles/PMC9152741/
- Villamor E, Villar LA, Lozano-Parra A, Herrera VM, Herrán OF. Serum fatty acids and progression
   from dengue fever to dengue hemorrhagic fever / dengue shock syndrome. Br J Nutr [Internet].
   2018 Oct 14 [cited 2022 Nov 7];120(7):787. Available from: /pmc/articles/PMC6150811/
- 11. Cárdenas MIE, Herrera VM, Montoya MCM, Parra AL, Moncayo ZMZ, García JPF, et al.
  Heterogeneity of dengue transmission in an endemic area of Colombia. PLoS Negl Trop Dis
  [Internet]. 2020 Sep 1 [cited 2022 Nov 7];14(9):e0008122. Available from:
  https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008122
- Rojas EM, Herrera VM, Miranda MC, Rojas DP, Gomez AM, Pallares C, et al. Clinical Indicators of
   Fatal Dengue in Two Endemic Areas of Colombia: A Hospital-Based Case–Control Study. Am J
   Trop Med Hyg [Internet]. 2019 [cited 2022 Nov 7];100(2):411. Available from:

### 564 /pmc/articles/PMC6367622/


- 56513.L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, et al. Symptomatic Dengue in566Children in 10 Asian and Latin American Countries. N Engl J Med [Internet]. 2016 Mar 24 [cited5672022 Nov 7];374(12):1155–66. Available from: https://pubmed.ncbi.nlm.nih.gov/27007959/
- 568 14. Gordon A, Gresh L, Ojeda S, Katzelnick LC, Sanchez N, Mercado JC, et al. Prior dengue virus
  569 infection and risk of Zika: A pediatric cohort in Nicaragua. PLoS Med [Internet]. 2019 [cited 2022
  570 Nov 8];16(1). Available from: /pmc/articles/PMC6342296/
- I5. Zambrana JV, Carrillo FB, Burger-Calderon R, Collado D, Sanchez N, Ojeda S, et al.
   Seroprevalence, risk factor, and spatial analyses of Zika virus infection after the 2016 epidemic in
   Managua, Nicaragua. Proc Natl Acad Sci U S A [Internet]. 2018 Sep 11 [cited 2022 Nov
   8];115(37):9294–9. Available from: /pmc/articles/PMC6140532/
- 575 16. Standish K, Kuan G, Avilés W, Balmaseda A, Harris E. High Dengue Case Capture Rate in Four
  576 Years of a Cohort Study in Nicaragua Compared to National Surveillance Data. PLoS Negl Trop Dis
  577 [Internet]. 2010 Mar [cited 2022 Nov 8];4(3):e633. Available from:
  578 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000633
- Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborío S, et al. Trends in patterns of
  dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis [Internet].
  2010 Jan [cited 2022 Nov 8];201(1):5–14. Available from:
  https://pubmed.ncbi.nlm.nih.gov/19929380/
- 18. Burger-Calderon R, Bustos Carrillo F, Gresh L, Ojeda S, Sanchez N, Plazaola M, et al. Agedependent manifestations and case definitions of pediatric Zika: a prospective cohort study.
  Lancet Infect Dis [Internet]. 2020 Mar 1 [cited 2022 Nov 8];20(3):371. Available from:
  /pmc/articles/PMC7085943/
- 19. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. Symptomatic Versus
  Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval
  between Infections and Study Year. PLoS Negl Trop Dis [Internet]. 2013 [cited 2022 Nov
  8];7(8):2357. Available from: /pmc/articles/PMC3738476/
- 591 20. Katzelnick LC, Narvaez C, Arguello S, Mercado BL, Collado D, Ampie O, et al. Zika virus infection
  592 enhances future risk of severe dengue disease. Science [Internet]. 2020 Aug 8 [cited 2022 Nov
  593 8];369(6507):1123. Available from: /pmc/articles/PMC8274975/
- 59421.Waggoner JJ, Balmaseda A, Gresh L, Sahoo MK, Montoya M, Wang C, et al. Homotypic Dengue595Virus Reinfections in Nicaraguan Children. J Infect Dis [Internet]. 2016 Oct 1 [cited 2022 Nov5968];214(7):986–93. Available from: https://academic.oup.com/jid/article/214/7/986/2388004
- 597 22. OhAinle M, Balmaseda A, Macalalad AR, Tellez Y, Zody MC, Saborío S, et al. Dynamics of Dengue
   598 Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific
   599 Immunity. Sci Transl Med [Internet]. 2011 Dec 12 [cited 2022 Nov 8];3(114):114ra128. Available
   600 from: /pmc/articles/PMC4517192/
- 601 23. Gutiérrez G, Gresh L, Pérez MÁ, Elizondo D, Avilés W, Kuan G, et al. Evaluation of the Diagnostic
  602 Utility of the Traditional and Revised WHO Dengue Case Definitions. PLoS Negl Trop Dis
  603 [Internet]. 2013 [cited 2022 Nov 8];7(8):2385. Available from: /pmc/articles/PMC3749970/
- 604 24. Jaenisch T, Tam DTH, Kieu NTT, Ngoc T, Nam NT, van Kinh N, et al. Clinical evaluation of dengue

605 606 607		and identification of risk factors for severe disease: protocol for a multicentre study in 8 countries. BMC Infect Dis [Internet]. 2016 Mar 11 [cited 2022 Nov 7];16(1). Available from: https://pubmed.ncbi.nlm.nih.gov/26968374/
608 609 610 611	25.	Jaenisch T, IDAMS, Sakuntabhai A, DENFREE, Wilder-Smith A, DengueTools. Dengue Research Funded by the European Commission-Scientific Strategies of Three European Dengue Research Consortia. PLoS Negl Trop Dis [Internet]. 2013 [cited 2022 Nov 8];7(12). Available from: /pmc/articles/PMC3861113/
612 613 614	26.	Brasil P, Vasconcelos Z, Kerin T, Gabaglia CR, Ribeiro IP, Bonaldo MC, et al. Zika virus vertical transmission in children with confirmed antenatal exposure. Nat Commun [Internet]. 2020 Dec 1 [cited 2022 Nov 8];11(1). Available from: /pmc/articles/PMC7360785/
615 616 617 618	27.	Thomas D, Radji S, Benedetti A. Systematic review of methods for individual patient data meta- analysis with binary outcomes. BMC Med Res Methodol [Internet]. 2014 Jun 19 [cited 2022 Nov 24];14(1):1–9.Availablefrom: https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-14-79
619 620 621	28.	Fortier I, Raina P, van den Heuvel ER, Griffith LE, Craig C, Saliba M, et al. Maelstrom Research guidelines for rigorous retrospective data harmonization. Int J Epidemiol [Internet]. 2017 Feb 1 [cited 2022 Nov 8];46(1):103. Available from: /pmc/articles/PMC5407152/
622 623 624 625	29.	Milhim BHGA, da Rocha LC, Terzian ACB, Mazaro CCP, Augusto MT, Luchs A, et al. Arboviral Infections in Neurological Disorders in Hospitalized Patients in São José do Rio Preto, São Paulo, Brazil. Viruses [Internet]. 2022 Jul 1 [cited 2022 Dec 1];14(7). Available from: https://pubmed.ncbi.nlm.nih.gov/35891468/
626 627 628 629	30.	Hortion J, Mutuku FM, Eyherabide AL, Vu DM, Boothroyd DB, Grossi-Soyster EN, et al. Acute Flavivirus and Alphavirus Infections among Children in Two Different Areas of Kenya, 2015. Am J Trop Med Hyg [Internet]. 2019 [cited 2022 Dec 1];100(1):170–3. Available from: https://pubmed.ncbi.nlm.nih.gov/30457092/
630 631 632 633	31.	Martínez RA, Díaz FA, Villar LA. Evaluación de la definición clínica de dengue sugerida por la Organización Mundial de la Salud. Biomédica [Internet]. 2005 Sep 1 [cited 2022 Nov 8];25(3):412–6. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/1365
634 635 636	32.	Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science [Internet]. 2017 Nov 17 [cited 2022 Nov 8];358(6365):929. Available from: /pmc/articles/PMC5858873/
637 638	33.	Standards   CDISC [Internet]. [cited 2022 Nov 8]. Available from: https://www.cdisc.org/standards
639 640 641 642	34.	R Core Team (2020) R A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria References - Scientific Research Publishing [Internet]. [cited 2022 Nov 17]. Available from: https://scirp.org/reference/referencespapers.aspx?referenceid=3064798
643 644	35.	BioStudies < EMBL-EBI [Internet]. [cited 2022 Dec 1]. Available from: https://www.ebi.ac.uk/biostudies/
645	36.	EGA European Genome-Phenome Archive [Internet]. [cited 2022 Dec 1]. Available from:


646		https://ega-archive.org/
647 648	37.	Pathogens [Internet]. [cited 2022 Dec 1]. Available from: https://www.ebi.ac.uk/ena/pathogens/v2/cohorts
649 650	38.	ENA Browser [Internet]. [cited 2022 Dec 1]. Available from: https://www.ebi.ac.uk/ena/browser/home
651 652	39.	An introduction to EMBL-EBI resources   EMBL-EBI Training [Internet]. [cited 2022 Dec 1]. Available from: https://www.ebi.ac.uk/training/events/introduction-embl-ebi-resources/
653		
654		
655 656		


Master Definition								Studies	Harmonization		
domain 🔻	Temp Variable names	Ŧ	definition 🔻	name 🔻	unit 🔻	type 🔻	Studies 🐨	Variables 👻	Harmo Potential Status per Variable (to be completed following the instructions below)	Harmo Potential Status detail per Variable ((to be completed following the instructions below)	Comments on harmonization rule
endpoints	age	1	* age of the patient at the day of measurement * reported by patient or family or official documents	#9ŧ	years	Integer	Nica- Cohorte Arbovirus	exp	1	1.2	Transformation: Substact(fecha_consulta - exp)
endpoints	age	1	* age of the patient at the day of measurement * reported by patient or family or official documents	890	years	Integer	Nica- Estudio Hospitalario	Edad	1	1.2	Transformation: DD-MM-YYYY -> YYYY-MM-DD
endpoints	age	4	" age of the patient at the day of measurement " reported by patient or family or official documents	age	years	Integer	IDAMS	dm_age	1	1.1	idéntico
endpoints	age	1	" age of the patient at the day of measurement " reported by patient or family or official documents	age	years	Integer	Col-AedesCohort	Edad	1	1.1	idéntico
endpoints	age	1	" age of the patient at the day of measurement " reported by patient or family or official documents	age	years	Integer	Col: Diagnosis Cohort	Edad	1	1.1	idéntico
endpoints	age	1	" age of the patient at the day of measurement " reported by patient or family or official documents	age	years	Integer	Col: Prognosis Cohort	Edad	1	1.1	idéntico
endpoints	age	1	* age of the patient at the day of measurement * reported by patient or family or official documents	age	years	Integer	Col: Seroprevalence Cohort	x	2	2.1	indisponible
endpoints	age	1	" age of the patient at the day of measurement " reported by patient or family or official documents	age	years	Integer	Brazil _ cohort of symptomatic pregnant women	x	2	2.1	indisponible

# Figure 2. Harmonization Potential




# Figure 3. DENV Seroptype Distribution





# Figure 4. Reported DENV, ZIKV, CHKV Cases






Figure 1. Harmonization Process